由CYP3A4调解的伊布迪拉斯特的代谢激活和细胞毒性
Lingwen Dong1, Xialing Hao1, Minglu Liu1
1Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, People's Republic of China.
用于神经疾病的IBD可能会导致肝损伤. 这项研究表明,IBD代谢过程中形成的活性环氧化物中间体与这种肝毒性有关,为不良影响提供了洞察力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 伊布迪拉斯 (IBD) 是一种非选择性固酶抑制剂,用于喘,多发性硬化症和神经病痛.
- IBD的临床使用与肝酶 (AST,ALT) 和肝体重升高有关,但肝毒性的潜在机制尚不清楚.
研究的目的:
- 为了研究IBD的代谢激活.
- 确定IBD生物激活及其观察到的肝毒性之间的相关性.
主要方法:
- 用小鼠和人类肝脏显微体和捕捉剂 (GSH,NAC,Cys) 化IBD以确定代谢物.
- 依赖NADPH的代谢物形成试验.
- 在小鼠体内研究以检测胆道和尿道结合物.
- 在初级肝细胞中评估IBD细胞毒性和CYP3A4抑制的影响.
主要成果:
- 一些IBD衍生的谷氨 (GSH),N-乙-L-氨酸 (NAC) 和氨酸 (Cys) 合物 (M1-M6) 在体外被确定.
- 代谢研究表明,反应性环氧化物中间体的形成.
- 发现这种环氧化物中间体以剂量依赖的方式与肝脏蛋白质结合.
- 鉴定出CYP3A4是主要负责IBD代谢激活的酶.
- 暴露于IBD降低了原发性肝细胞存活率,这种效应被基托可纳 (一种CYP3A4抑制剂) 减弱.
结论:
- 在IBD代谢过程中形成的反应性环氧化物中间体可能是IBD诱导的肝毒性.
- 这一发现为与IBD临床使用相关的肝损伤机制提供了关键的见解.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Drug Biotransformation: Overview
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inhibition of Cdk Activity
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
